We advance virtual clinical trials with innovative, integrated AI technology that improves safety and accuracy.
Did you know every year
is lost to failed human trials?
of innovations fail during human trials?
of clinical trials are delayed due to participants recruitment issues?
What is status quo❓
Several issues with human trials:
High cost
Long timelines
High risk
Lack of participants
1
Human trials cost millions, often tens or hundreds of millions. Much of this money is spent before teams know if an idea will actually work.
2
Running trials with real people takes years. Long setup, recruitment, and approval cycles delay progress before results are even known.
3
Many trials are delayed or canceled because not enough people can be recruited or retained. This slows progress and wastes resources.
4
Most trials fail after years of testing when the cost and risk are already high. Over 50% of trial failures occur in late stages, after most costs have already been spent.
Reduced costs from millions and even billions to hundreds.
Run a virtual clinical trial in under 5 minutes.
Unlimited virtual participants powered by human digital twins.
Predict late-stage human intervention success rates with uncertainty scores.
INTRODUCING
Xtwin
A virtual clinical trial SaaS platform integrating AI and human digital twin technologies
Patent pending. This device is in active development, designed to meet FDA and U.S. regulatory requirements. It is available for beta access distribution.
"Digital twins have the potential to remove common medical risks involved in patient monitoring and treatment, providing a framework for optimal decision-making,"
Yulia Gel,
program director in the US National Science Foundation
“With the appropriate safeguards in place, artificial intelligence has transformative potential to advance clinical research and accelerate medical product development to improve patient care.”
Robert M. Califf, M.D.,
FDA Commissioner
We are passionate about pioneering futuristic technologies in healthcare.
Clinicians, parents, partners, and investors are invited to connect with us. Whether you want to provide feedback, explore collaboration, or support our mission, we welcome your outreach and personally review every message we receive.
